Pinpointing the Factors Affecting Clinical Study Experiences of Pulmonary Fibrosis Patients
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Power Life Sciences Inc.
- Study ID
- NCT05899556
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what research attributes affect the completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of pulmonary fibrosis patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future pulmonary fibrosis patients.
Key Dates
- Start date
- Jul 31, 2024
- Status verified
- Jun 2023
- Primary completion
- Jul 31, 2025
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Number of pulmonary fibrosis patients who decide to participate in a clinical study [ Time Frame: 3 months ]
Central Contacts
- Michael B Gill4159004227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Power Life Sciences | San Francisco | California | 94107 | - |
Find similar trials in San Francisco, CA
Related Studies
- Global Utilization And Registry Database for Improved preservAtion of doNor LUNGsEnrolling By Invitation · Paragonix Technologies · Phoenix, Arizona
- FAPI PET for Lung FibrosisEARLY_PHASE1 · Recruiting · University of California, Los Angeles · Los Angeles, California
- Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary FibrosisRecruiting · University of California, Los Angeles · Los Angeles, California
- A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisPHASE2 · Recruiting · Avalyn Pharma Inc. · Birmingham, Alabama